Early 12-Month Blood Test Reveals Ongoing MS Activity

Credibility

Interest

Share:2 min read

Key Takeaway

A 12-month blood test using normalized scores can show whether MS-related brain or nerve injury markers stay high and who may need closer follow-up.

What They Found

The study looked at two blood markers: sNfL, which rises when nerve fibers are damaged, and sGFAP, which rises when support cells in the brain are stressed or injured. Researchers adjusted different lab tests to a common scale (Z scores) so results could be compared no matter which machine was used; a Z score just shows how far a number is from what’s normal for a person like you. After treatment with ocrelizumab (a medicine that lowers immune attacks), people with relapsing MS usually had lower sNfL, while sGFAP stayed about the same on average. Patients who started with both markers high tended to keep higher levels over time, unlike those with progressive MS who stayed more stable. If a person did not get at least a 50% drop in Z score by month 12, they were much more likely to still have high marker levels at 24 months, suggesting ongoing injury or stress to the brain or nerves.

Who Should Care and Why

People with MS and their caretakers should care because a simple blood check at 12 months can help show whether a treatment is lowering signs of nerve damage, much like a progress photo shows if a workout plan is working. Doctors and nurses can use this information to decide if a patient needs closer visits or different treatment, similar to how a mechanic might check a car more often if warning lights stay on. Patients with relapsing MS, especially those who start with high marker levels, may benefit most from this check because they were the group that showed bigger changes. Caregivers can use these results to support scheduling more follow-up or to ask questions about treatment choices when markers stay high. Knowing a clear rule (50% drop by 12 months) makes it easier to spot who might need extra attention without guessing.

Important Considerations

This study pooled data from several centers and used adjusted scores to compare tests, but it is not the same as a randomized trial proving that changing care based on these scores improves outcomes. The findings apply to people treated with ocrelizumab, so results might differ with other MS drugs. Also, blood markers are one piece of information and should be used together with symptoms, exams, and MRI scans before making major care decisions.

AI-generated summary — for informational purposes only, not medical advice

Categories:

MS Diagnostics Clinical Trials Early Research

Article Topics:

Glial fibrillary acidic proteinMultiple sclerosisNeurofilament light chainOcrelizumabSerum biomarkersZ scores

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like Journal of neurology often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News